カリフォルニア州における強皮症の臨床試験
カリフォルニア州内の拠点で、強皮症に関する13件の研究が参加者を募集しています。
カリフォルニア州内の都市
公式研究テキスト（英語）
A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
- University of California Los Angeles, Los Angeles
- Paradigm Clinical Research - San Diego, San Diego
- Stanford University School of Medicine, Stanford
- 他1件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/30更新 · NCT07497087A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis
- UCLA Ronald Reagan University of California Los Angeles Medical Center, Los Angeles
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/24更新 · NCT06655155Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- University of California Davis Comprehensive Cancer Center, Sacramento
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/23更新 · NCT03816345A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
- Loma Linda University Medical Center, Loma Linda
被験者募集中第1相
18歳〜74歳 · 全性別 · 2026/09/10更新 · NCT07085104A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
- GSK Investigational Site, Los Angeles
- GSK Investigational Site, Los Angeles
- GSK Investigational Site, Los Angeles
- 他1件
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/09/08更新 · NCT05878717FT839 in Autoimmune Diseases
- Providence Medical Foundation, Fullerton
被験者募集中第1/2相
18歳〜70歳 · 全性別 · 2026/09/02更新 · NCT07800871A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
- UC San Diego Health, La Jolla
- Stanford University Medical Center, Redwood City
被験者募集中第1相
18歳〜70歳 · 全性別 · 2026/08/28更新 · NCT06925542Platform Clinical Study for Conquering Scleroderma
- Keck School of Medicine at USC Medical Center, Los Angeles
- Cedars-Sinai Medical Center, Los Angeles
- Stanford University Medical Center, Palo Alto
被験者募集中第2相
18歳以上 · 全性別 · 2026/08/18更新 · NCT06195072A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
- Nkarta Investigational Site, Orange
被験者募集中第1/2相
18歳〜75歳 · 全性別 · 2026/08/07更新 · NCT06733935AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
- Artiva Investigational Site Chula Vista, Chula Vista
- Artiva Investigational Site Covina, Covina
- Artiva Investigational Site Los Alamitos, Los Alamitos
- 他3件
被験者募集中第2相
18歳以上 · 全性別 · 2026/07/31更新 · NCT06991114A Study of AZD0120 in Autoimmune Diseases
- Research Site, Stanford
被験者募集中第1相
18歳〜75歳 · 全性別 · 2026/07/28更新 · NCT07295847A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
- Wallace Rheumatic Center, Beverly Hills
- Providence Medical Foundation, Fullerton
- University of California Irvine, Irvine
- 他2件
被験者募集中第1相
12歳〜70歳 · 全性別 · 2026/05/22更新 · NCT06308978Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)
- aTyr Investigative Site, Los Angeles
- aTyr Investigative Site, San Diego
被験者募集中第2相
18歳以上 · 全性別 · 2025/05/07更新 · NCT05892614ClinicalTrials.govより、2026/10/03時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。